News Oxurion Announces Key Amendments to Atlas and Kreos/Pontifax Agreements Enabling KALAHARI Trial to Progress to Topline Results in 2023 Continue Reading Previous Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPDNext Accenture Invests in Open Cosmos to Expand Access to Satellite Data Related Stories News Enablence Technologies Announces Adoption of Equity Incentive Plan News AISIX Solutions Inc. Announces Revocation of Management Cease Trade Order News Ynvisible Announces Closing of Final Tranche of Non-Brokered Private Placement News Trenchant Technologies Capital Corp. Announces Private Placement Offering of up to $1 Million Convertible Debentures News Demenaris Launches Heat-Safety Protocol for Montreal Summer Moves News Cheelcare Closes $3.02 Million Upsized Non-Brokered Private Placement
